Quotables
"Fooling around with alternating current is just a waste of time. Nobody will use it, ever."
Thomas Edison ; 1889
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120129933 | CERAMIDE DIMERS AND USE THEREOF AS PHARMACEUTICAL PREPARATION OR COSMETIC PREPARATION The invention relates to ceramide dimers which are constructed from two ceramide molecules which are crosslinked to each other via their lipophilic end. The ceramide molecules thereby have at least one hydrophilic group at their hydrophilic end for increasing the hydrat... | 05/24/2012 |
| 20120129861 | COMPOSITIONS OF DIBROMOMALONAMIDE AND THEIR USE AS BIOCIDES A biocidal composition comprising 2,2-dibromomalonamide and an aldehyde-based biocidal compound, and its use for the control of microorganisms in aqueous and water-containing systems.... | 05/24/2012 |
| 20120108878 | Novel Chemistries, Solutions, and Dispersal Systems for Decontamination of Chemical and Biological Systems The present invention relates generally to chemical and biological decontamination solutions and methods of using them. The invention is useful for decontaminating a wide range of compounds and organisms. In particular, the systems, methods, solutions, and formulations ... | 05/03/2012 |
| 20120108562 | THERAPEUTIC COMPOSITIONS AND METHODS PAD4 inhibitory compositions and methods for their use in treatment of cancer and autoimmune disease are provided according to embodiments of the present invention.... | 05/03/2012 |
| 20120083493 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY Provided are small-molecule Trp-p8 modulators, including Trp-p8 agonists and Trp-p8 antagonists, and compositions comprising small-molecule Trp-p8 agonists as well as methods for identifying and characterizing novel small-molecule Trp-p8 modulators and methods for decre... | 04/05/2012 |
| 20120083533 | USE OF AMIDES OF MONO- AND DICARBOXYLIC ACIDS IN THE TREATMENT OF RENAL DISEASES A therapy for renal diseases, in particular renal diseases which develop in diabetic patients or patients who have been subjected to a treatment with an antitumor chemotherapy such as a platinum derivative and more generally cytotoxic drugs at renal level for treating o... | 04/05/2012 |
| 20120083440 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH Bone targeted compounds and methods are provided. Compounds can include a Bone Targeting Portion (RT), having an affinity for bone; a Bone Active Portion (RA) for interacting with and affecting bone; and a Linking Portion (RL) connecting... | 04/05/2012 |
| 20120070369 | HIF INHIBITORS AND USE THEREOF The present invention is directed to HIF inhibitors and methods of preventing cell proliferation, reducing inflammation, and treating an angiogenic disease or disorders.... | 03/22/2012 |
| 20120071528 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA The invention is directed to novel compounds of Formula I: as well as its stereoisomers and/or pharmaceutically acceptable salts, for the treatment of diabetes and diabetes associated dyslipidemia.... | 03/22/2012 |
| 20120070394 | METHIONINE-DERIVED PEPTIDOMIMETICS AND THEIR USE IN THE PROTECTION OF MITOCHONDRIA OF CUTANEOUS CELLS The invention concerns a methionine-derived peptidomimetic represented by the following general formula (II):
| |
| 20120071539 | COMPOUNDS AND METHODS FOR MODULATING THE SILENCING OF A POLYNUCLEOTIDE OF INTEREST Methods and compositions comprising chemical compounds that modulate the silencing of a polynucleotide of interest in a cell are provided. Such chemical compounds when used in combination with an appropriate silencing element can be used to modulate (increase or decreas... | 03/22/2012 |
| 20120053212 | METHODS OF TREATING HUMANS UNDERGOING INJECTION OF A CONTRAST AGENT A human undergoing an injection of a contrast agent is treated by the administration of an iron chelator. Administration of the iron chelator can essentially prevent the onset of acute renal failure in a human. Administration of the iron chelator can reduce the severity... | 03/01/2012 |
| 20120046272 | Novel Therapeutic Compounds The present invention describes a series of therapeutically active compounds of formula I,
that are useful for treating a disorder in a mammal. In the f... | 02/23/2012 |
| 20120046226 | Combined Treatment of Multiple Sclerosis The invention concerns a novel treatment multiple sclerosis, based on induced anaemia, followed by administration of an erythropoiesis-stimulating agent (ESA). In a preferred embodiment, the ESA is darbopoietin alpha, CERA or Hematide. The anaemia is induced by successi... | 02/23/2012 |
| 20120041067 | Methods of Inducing Terminal Differentiation The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibit... | 02/16/2012 |
| 20120039909 | EPIGENETIC MECHANISMS RE-ESTABLISH ACCESS TO LONG-TERM MEMORY AFTER NEURONAL LOSS The invention relates to methods and products for enhancing and improving recovery of lost memories. In particular the methods are accomplished through the increase of histone acetylation.... | 02/16/2012 |
| 20120041063 | ANTITUMORAL COMPOUNDS A compound of general formula (I) wherein, R11, R12, R13, R14, R15, W, Y, R1, R2, R3, R4, R5, and R6 take various meanings for use in the t... | 02/16/2012 |
| 20120039893 | MUTANT SMOOTHENED AND METHODS OF USING THE SAME The emergence of mutations in tyrosine kinases following treatment of cancer patients with molecular-targeted therapy represents a major mechanism of acquired drug resistance. Here, we describe a mutation in the serpentine receptor, Smoothened (SMO), which results in re... | 02/16/2012 |
| 20120028995 | NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS The invention relates to compounds of general formula (I) as set forth in the claims as well as to the use of the compounds of the general formula (1) in the medical field, specifically for use in the suppression of DNA synthesis and inflammatory cytokine production as ... | 02/02/2012 |
| 20120027844 | COMPOUNDS, THEIR SYNTHESES, COMPOSITIONS, AND METHODS TO TREAT CANCER Compounds and their syntheses are disclosed herein. Compositions and pharmaceutical compositions comprising a compound are also described, and include compositions also comprising liposomes. Methods for the treatment of cancer in animals comprising administering a compo... | 02/02/2012 |
| 20120029067 | Polyphenol Proteasome Inhibitors, Synthesis, and Methods of Use The present invention relates to synthetic green tea derived polyphenolic compounds, their modes of syntheses, and their use in inhibiting proteasomal activity and in treating cancers. The present invention is also directed to pharmaceutical compositions useful in metho... | 02/02/2012 |
| 20120029083 | POLYMORPHIC FORMS OF ALISKIREN HEMIFUMARATE AND PROCESS FOR PREPARATION THEREOF Provided are amorphous and polymorphic forms of aliskiren hemifumarate, pharmaceutical compositions thereof, and processes for their preparation.... | 02/02/2012 |
| 20120021989 | GENETIC MARKERS FOR RISK MANAGEMENT OF ATRIAL FIBRILLATION AND STROKE The invention relates to procedures and methods of determining a susceptibility to cardiac arrhythmia, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with risk of th... | 01/26/2012 |
| 20120016035 | Synergistic combinations comprising a renin inhibitor for cardiovascular diseases The invention relates to a combination comprising the renin inhibitor of formula (I) or a pharmaceutically acceptable salt thereof.... | 01/19/2012 |
| 20120015992 | Napthalene-Based Inhibitors of Anti-Apoptotic Proteins Methods of using apogossypol and its derivatives for treating inflammation is disclosed. Also, there is described a group of compounds having structure A, or a pharmaceutically acceptable salt, hydrate, N-oxide, or solvate thereof are provided: 01/19/2012 | |
| 20120010295 | Synergistic combinations comprising a renin inhibitor for cardiovascular diseases The invention relates to a combination comprising the renin inhibitor of formula (I) or a pharmaceutically acceptable salt thereof.... | 01/12/2012 |
| 20120004227 | CYCLOHEXANE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISM The present invention discloses novel cyclohexane derivatives having NPY Y5 receptor antagonistic activity. Specifically, the present invention discloses a compound represented by the formula (I), or a pharmaceutically acceptable salt or a solvate thereof: 01/05/2012 | |
| 20120004243 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS The invention concerns a compound of the Formula (I), wherein Qa is heteroaryl and is substituted with halogeno; R1 and R2 are hydrogen; and Qb is phenyl or heteroaryl, and Qb may optionally bear 1 or 2 substituents selected from hydroxy, halogeno and (1-6C)alkyl, or a ... | 01/05/2012 |
| 20120004312 | Synergistic combinations comprising a renin inhibitor for cardiovascular diseases The invention relates to a combination comprising the renin inhibitor of formula (I) or a pharmaceutically acceptable salt thereof.... | 01/05/2012 |
| 20120004209 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11β-hydroxy-steroid d... | 01/05/2012 |
| 20120004311 | OPTICALLY PURE APOGOSSYPOL DERIVATIVE AS PAN-ACTIVE INHIBITOR OF ANTI-APOPTOTIC B-CELL LYMPHOMA/LEUKEMIA-2 (BCL-2) A compound of Formula I: or a pharmaceutically acceptable salt thereof is disclosed. In addition, pharmaceutical compositions thereof, methods for preparing and methods for using this compound or composition ... | 01/05/2012 |
| 20120004310 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule.... | 01/05/2012 |
| 20120003242 | MODULATING PDX-1 WITH PCIF1, METHODS AND USES THEREOF This invention relates to PCIF1 and its use as a target for the improvement of pancreatic islet β cell mass and function in diabetes. Specifically, the invention relates to the use of compounds capable of modulating the expression or function of PCIF1 and their effect ... | 01/05/2012 |
| 20110319454 | DERIVATIVES OF CYCLOALKYL- AND CYCLOALKENYL-1,2-DICARBOXYLIC ACID COMPOUNDS HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY The invention provides well defined compounds having FPRL-1 agonist or antagonist activity. As such, the compounds of the invention are useful for treating a variety of ocular disorders.... | 12/29/2011 |
| 20110312997 | Inhibition of WDR5 Interaction with Its Binding Partners Peptidomimetics that inhibit the interaction between MLL1 and WDR5 are disclosed. Methods of inhibiting MLL1 activity and methods of treating cancers also are disclosed.... | 12/22/2011 |
| 20110312964 | CYSTEINE PROTEASE INHIBITORS Compounds of the formula I wherein R1a is H; and R1b is C1-C6 alkyl, Carbocyclyl or Het; or R1a | |
| 20110312875 | PEPTIDIC COMPOUNDS The present invention provides a compound of formula I, II, III and IV as defined herein and pharmaceutically acceptable derivatives thereof. The present invention further provides use of the compounds of the present invention in the treatment of bacterial infection and... | 12/22/2011 |
| 20110306600 | NOVEL THERAPEUTIC COMPOUNDS The invention discloses a number of therapeutic compounds and a method of treating a disorder in mammal.... | 12/15/2011 |
| 20110306668 | CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID A process for synthesizing and screening solution phase derived libraries of fenbufen and ethacrynic acid is provided in the present invention. Compounds in the present invention having cytotoxicities are useful for a variety of therapeutic applications.... | 12/15/2011 |
| 20110301235 | ORGANOSELENIUM COMPOUNDS AND USES THEREOF Provided herein are organoselenium compounds and pharmaceutical compositions thereof. Also provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders using the compounds and pharmaceutical compositions provided herein.... | 12/08/2011 |
